Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03666273 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03666273 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 60 participants.
The verdict
NCT03666273, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it affects the body and to try to find the best dose of the new drug to give to participants and to obtain a preliminary assessment of the tumor response efficacy in the recurrent or metastatic Head and Neck Cancer.
Interventions
- DRUG Bapotulimab (BAY1905254)
- DRUG Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2018-09-12 |
| Est. Completion | 2024-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03666273
The ClinicalTrials.gov registry entry for NCT03666273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bapotulimab (BAY1905254) is the first listed.
NCT03666273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03666273 about?
NCT03666273 is a clinical study titled "Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.". This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it affects the body and to try to find the best dose of the new drug to give to...
What is the current status of trial NCT03666273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2018-09-12. Estimated completion is 2024-05-15.
What interventions are being tested in trial NCT03666273?
The interventions under investigation include: Bapotulimab (BAY1905254) (DRUG), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®) (DRUG).
Who is sponsoring clinical trial NCT03666273?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.